Nd Rfl Us75062e1064 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Company on track to complete enrollment in ongoing pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 by year end 2023 . | May 15, 2023

United statesWilliam conklingRafael holdings incCompany boardCompany trappsolCompany phaseRafael holdingsCyclo therapeutics incCyclo therapeuticsChief executive officerFinancial resultsFirst quarterExpanded accessNc stock exchangePress releaseNd rfl us75062e1064